Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hypertension. Sold as Diovan Hct. Every FDA application for this active ingredient: 1 branded and 12 generic.
As of Nov 15, 2026, FDA lists 13 applications for Hydrochlorothiazide; Valsartan (sold as Diovan Hct), first approved Mar 6, 1998, with 3 new uses approved and 0 published complete response letters.
First approved: Mar 6, 1998
Applications: 13
New uses approved: 3
Complete response letters: 0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
DIOVAN HCT 160-12.5 MG TAB: $11.48 per unitBrand · +3% in a year
DIOVAN HCT 320-25 MG TABLET: $16.38 per unitBrand · +2% in a year
DIOVAN HCT 80-12.5 MG TABLET: $10.56 per unitBrand · +3% in a year
Clinical Trials
1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Novartis
Mylan Pharms Inc
Alembic
Zydus Lifesciences